Evidence-based risk stratification to target therapies in acute coronary syndromes.
Cannon
Christopher P
CP
D000208:Acute Disease; D000787:Angina Pectoris / Q000150:complications / Q000628:therapy; D000925:Anticoagulants / Q000627:therapeutic use; D015415:Biomarkers / Q000032:analysis; D006328:Cardiac Catheterization; D000077144:Clopidogrel; D003327:Coronary Disease / Q000150:complications / Q000628:therapy*; D004562:Electrocardiography; D017984:Enoxaparin / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000150:complications / Q000517:prevention & control; D018570:Risk Assessment; D012307:Risk Factors; D012720:Severity of Illness Index; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D014336:Troponin / Q000032:analysis
D000925:Anticoagulants; D015415:Biomarkers; D017984:Enoxaparin; D005343:Fibrinolytic Agents; D014336:Troponin; D000077144:Clopidogrel; D013988:Ticlopidine